Trevi Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -34 | -31 | -38 | |
EBITDA | -14,912 | -8,301 | -11,779 | -12,284 |
EBIT | -14,946 | -8,332 | -11,817 | -12,322 |
Net Income | -13,192 | -8,316 | -11,802 | -12,301 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -16,791 | 5,846 | -10,892 | -10,101 |
Cash | 19,412 | 18,914 | 56,869 | 117,058 |
Basic Shares | 145,592 | 145,502 | 145,104 | 130,350 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -132 | -147 | -123 | -43 |
EBITDA | -42,679 | -47,790 | -28,583 | -29,864 |
EBIT | -42,823 | -47,937 | -28,706 | -29,907 |
Net Income | -42,759 | -47,911 | -29,065 | -29,152 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -24,241 | |||
Free Cash Flow | -42,101 | -38,291 | -31,847 | -28,334 |
Cash | 18,914 | 34,097 | 32,397 | 12,589 |
Basic Shares | 145,104 | 101,041 | 99,033 | 64,541 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.09 |
2025-12-31 | -$0.06 |
2025-09-30 | -$0.08 |
2025-06-30 | -$0.09 |